Dopamine receptor D4

DRD4
Identifiers
AliasesDRD4, D4DR, dopamine receptor D4
External IDsOMIM: 126452; MGI: 94926; GeneCards: DRD4
Orthologs
DatabasesNCBI: entry; OMA: entry
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_000797

NM_007878

RefSeq (protein)

NP_000788

NP_031904

Location (UCSC)Chr 11: 0.64 – 0.64 MbChr 7: 140.87 – 140.88 Mb
PubMed search
Wikidata
View/Edit HumanView/Edit Mouse

The dopamine receptor D4 is a dopamine D2-like G protein-coupled receptor encoded by the DRD4 gene on chromosome 11 at 11p15.5.

Like other D2-like receptors, the D4 receptor is activated by dopamine and inhibits adenylate cyclase, reducing intracellular levels of cyclic AMP.

The DRD4 gene contains several polymorphisms, including a variable number tandem repeat (VNTR) in exon 3. These variants have been studied for associations with attention deficit hyperactivity disorder (ADHD), novelty seeking, and cognitive development.

Gene

Polymorphisms

The human protein is coded by the DRD4 on chromosome 11 located in 11p15.5.

There are slight variations (mutations/polymorphisms) in the human gene:

  • A 48-base pair VNTR in exon 3
  • C-521T in the promoter
  • 13-base pair deletion of bases 235 to 247 in exon 1
  • 12 base pair repeat in exon 1
  • Val194Gly
  • A polymorphic tandem duplication of 48 bp

The 48-base pair variable number tandem repeat (VNTR) in exon 3 ranges from 2 to 11 repeats. The 7-repeat (7R) variant of DRD4 is known as DRD4-7R. Alleles with 6 to 10 repeats are described as "long" alleles.

Population variation and evolution

Allele frequencies vary greatly between populations; for example, the 7-repeat variant is more frequent in the Americas than in Asia.

The 48-base pair VNTR has been studied in relation to human evolution and behavioral variation across cultures. The 7R allele appears to have been selected for about 40,000 years ago. In 1999, Chen and colleagues observed that populations that had migrated farther during the period from 30,000 to 1,000 years ago had higher frequencies of 7R/long alleles. They also reported higher frequencies of 7R alleles in nomadic populations than in sedentary populations.

A subsequent study reported better health status among nomadic Ariaal men carrying 7R alleles, but slightly poorer health among carriers in recently sedentary Ariaal populations.

Structure

The structure of DRD4 has been reported in complex with the antipsychotic drug nemonapride.

Function

Signaling

As with other dopamine receptor subtypes, the D4 receptor is activated by the neurotransmitter dopamine. The D4 receptor belongs to the D2-like family. Activation inhibits the enzyme adenylate cyclase, thereby reducing the intracellular concentration of the second messenger cyclic AMP.

Dopamine is more potent at D4 receptor variants with 2 or 7 repeats than at the variant with 4 repeats. The 7-repeat variant has also been reported to respond less strongly to dopamine.

Cognition

Adults and children with the DRD4 7-repeat polymorphism show variations in auditory-evoked gamma oscillations, which may be related to attention processing.

Several studies have shown that agonists that activate the D4 receptor increase working memory performance and fear acquisition in monkeys and rodents according to a U-shaped dose response curve. However, antagonists of the D4 receptor reverse stress-induced or drug-induced working memory deficits. Gamma oscillations, which may be correlated with cognitive processing, can be increased by D4R agonists, but are not significantly reduced by D4R antagonists.

Pharmacology

Chemical structures of representative D4-preferring ligands.

Agonists

  • 13-Hydroxy-LSD – EC50Tooltip half-maximal effective concentration = 36 pM, among the most potent known
  • 14-Hydroxy-LSD – EC50Tooltip half-maximal effective concentration = 1.6 nM
  • LSD – EC50Tooltip half-maximal effective concentration = 14 nM, 380-fold weaker than 13-hydroxy-LSD
  • WAY-100635: potent full agonist, with 5-HT1A antagonistic component
  • A-412,997: full agonist, > 100-fold selective over a panel of seventy different receptors and ion channels
  • ABT-724 - developed for treatment of erectile dysfunction
  • ABT-670 - better oral bioavailability than ABT-724
  • FAUC 316: partial agonist, > 8600-fold selective over other dopamine receptor subtypes
  • FAUC 299: partial agonist
  • F-15063: antipsychotic with partial D4 agonism
  • (E)-1-aryl-3-(4-pyridinepiperazin-1-yl)propanone oximes
  • PIP3EA: partial agonist
  • Flibanserin - partial agonist
  • PD-168,077 - D4 selective but also binds to α1A, α2C and 5HT1A
  • CP-226,269 - D4 selective but also binds to D2, D3, α2A, α2C and 5HT1A
  • Ro10-5824 – partial agonist
  • Roxindole – D4 selective but also D2 and D3 autoreceptor agonist, 5HT1A receptor agonist, serotonin reuptake inhibitor)
  • Apomorphine – D4 selective but also D2 and D3 agonist, α-adrenergic and serotonergic weak antagonist
  • Nuciferine - D4 full selective but also partial D2 and D5 agonist

Antagonists

Inverse agonists

  • FAUC F41: inverse agonist, subtype selectivity of more than 3 orders of magnitude over D2 and D3

Behavioral and developmental associations

Novelty seeking

Despite early findings of an association between the DRD4 48bp VNTR and novelty seeking (a normal characteristic of exploratory and excitable people), a 2008 meta-analysis compared 36 published studies of novelty seeking and the polymorphism and found no effect. Results are consistent with novelty-seeking behavior being a complex trait associated with many genes, and the variance attributable to DRD4 by itself being very small. The meta-analysis of 11 studies did find that another polymorphism in the gene, the -521C/T, showed an association with novelty seeking. While human results are not strong, research in animals has suggested stronger associations and new evidence suggests that human encroachment may exert selection pressure in favor of DRD4 variants associated with novelty seeking.[clarification needed]

Cognitive development

Several studies have suggested that parenting may affect the cognitive development of children with the 7-repeat allele of DRD4. Parenting that has maternal sensitivity, mindfulness, and autonomy–support at 15 months was found to alter children's executive functions at 18 to 20 months. Children with poorer quality parenting were more impulsive and sensation seeking than those with higher quality parenting. Higher quality parenting was associated with better executive control in 4-year-olds.

Clinical significance

The D4 receptor has been linked to many neurological and psychiatric conditions, including schizophrenia and bipolar disorder, addictive behaviors, Parkinson's disease, and eating disorders such as anorexia nervosa.

Variants of DRD4 have also been associated with attention deficit hyperactivity disorder (ADHD). Several meta-analyses have linked the 7-repeat (7R) variant to susceptibility to ADHD.

Variants of DRD4 have been associated with autonomic nervous system dysfunction.[citation needed] A weak association has also been drawn between DRD4 and borderline personality disorder.[citation needed]

The D4 receptor is also a target for drugs that treat schizophrenia and Parkinson's disease.

Michael Connelly's 2020 crime novel Fair Warning (ISBN 978-0-316-53942-5) revolves around a serial killer who uses DNA profiles obtained on the Dark Web to target female victims, specifically those whose DRD4 profiles allegedly make them more susceptible to risk taking and sexual promiscuity.

See also